J Korean Diabetes.  2024 Sep;25(3):150-156. 10.4093/jkd.2024.25.3.150.

Management Strategies for Young-Onset Type 2 Diabetes Mellitus: An Integrated Approach

• Seo MH
• Kwak SH

• KMID: 2559571
• DOI: http://doi.org/10.4093/jkd.2024.25.3.150

Abstract

The prevalence of young-onset type 2 diabetes is increasing rapidly worldwide along with the incidence of obesity, including in Korea. Compared with later onset type 2 diabetes, patients with young-onset type 2 diabetes have a higher risk of microvascular complication, macrovascular complication, and disease-related mortality. Thus, integrated attention and management of associated pathobiological, socioeconomic, and mental health factors are needed. Based on the very few evidence-based studies in management, in this review, we describe strategies for the integrated management for young-onset type 2 diabetes.

Keyword

Diabetes mellitus, type 2; Disease management; Patient-centered care; Young adult

Reference

1.Perng W., Conway R., Mayer-Davis E., Dabelea D. Youth-onset type 2 diabetes: the epidemiology of an awakening epi-demic. Diabetes Care. 2023. 46:490–9.

2.The Lancet Diabetes & Endocrinology. Alarming rise in young-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2024. 12:433.

3.Choi HH., Choi G., Yoon H., Ha KH., Kim DJ. Rising incidence of diabetes in young adults in South Korea: a national cohort study. Diabetes Metab J. 2022. 46:803–7.

4.Diabetes UK. Reverse the trend. Reducing type 2 diabetes in young people. Available from: https://www.diabetes.org.uk/about-us/our-impact/how-we-influence-change/our-work-in-parliament/reverse-the-trend-report.

5.International Diabetes Federation. IDF Diabetes Atlas. 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition/.

6.Korean Diabetes Association. Diabetes fact sheet in Korea 2022. Seoul: Korean Diabetes Association;2023.

7.Magliano DJ., Sacre JW., Harding JL., Gregg EW., Zimmet PZ., Shaw JE. Young-onset type 2 diabetes mellitus: implications for morbidity and mortality. Nat Rev Endocrinol. 2020. 16:321–31.

8.Yang YS., Han K., Sohn TS., Kim NH. Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need. Korean J Intern Med. 2021. 36:1049–58.

9.Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol. 2023. 11:731–42.

10.Misra S., Ke C., Srinivasan S., Goyal A., Nyriyenda MJ., Florez JC, et al. Current insights and emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2023. 11:768–82.

11.Choi JH., Lee KA., Moon JH., Chon S., Kim DJ., Kim HJ, et al. 2023 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2023. 47:575–94.

12.Hodgson S., Huang QQ., Sallah N; Genes & Health Re-search Team., Griffiths CJ., Newman WG, et al. Integrating polygenic risk scores in the prediction of type 2 diabetes risk and subtypes in British Pakistanis and Bangladeshis: a population-based cohort study. PLoS Med. 2022. 19:e1003981.

13.Shield JP., Lynn R., Wan KC., Haines L., Barrett TG. Management and 1 year outcome for UK children with type 2 diabetes. Arch Dis Child. 2009. 94:206–9.

14.Andela S., Burrows TL., Baur LA., Coyle DH., Collins CE., Gow ML. Efficacy of very low-energy diet programs for weight loss: a systematic review with meta-analysis of intervention studies in children and adolescents with obesity. Obes Rev. 2019. 20:871–82.

15.Lean MEJ., Leslie WS., Barnes AC., Brosnahan N., Thom G., McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, clus-terrandomised trial. Lancet Diabetes Endocrinol. 2019. 7:344–55.

16.TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013. 36:1749–57.

17.Taheri S., Zaghloul H., Chagoury O., Elhadad S., Ahmed SH., El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020. 8:477–89.

18.Shah AS., Zeitler PS., Wong J., Pena AS., Wicklow B., Arslanian S, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022. 23:872–902.

19.Inge TH., Courcoulas AP., Jenkins TM., Michalsky MP., Helmrath MA., Brandt ML., Teen-LABS Consor-tium, et al. Weight loss and health status 3 years after bariatric surgery in adolescents. N Engl J Med. 2016. 374:113–23.

20.Chan JCN., Paldánius PM., Mathieu C., Stumvoll M., Mat-thews DR., Del Prato S. Early combination therapy de-layed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab. 2021. 23:245–51.

21.Tamborlane WV., Barrientos-Pérez M., Fainberg U., Frim-er-Larsen H., Hafez M., Hale PM., Ellipse Trial Investigators, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019. 381:637–46.

22.Arslanian SA., Hannon T., Zeitler P., Chao LC., Bouch-er-Berry C., Barrientos-Pérez M., AWARD-PEDS Investigators, et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022. 387:433–43.

23.Tamborlane WV., Laffel LM., Shehadeh N., Isganaitis E., Van Name M., Ratnayake J, et al. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol. 2022. 10:341–50.

24.Laffel LM. Summary of research: efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Diabetes Ther. 2024. 15:893–6.